103 related articles for article (PubMed ID: 18798589)
1. Familial dysbetalipoproteinemia: a potentially fatal disorder.
Bari AU; Hashim R; Rahman SB; Hussain M
J Coll Physicians Surg Pak; 2008 Aug; 18(8):506-8. PubMed ID: 18798589
[TBL] [Abstract][Full Text] [Related]
2. The role of lipid management in diabetes.
Ganda OP
Cardiol Clin; 2005 May; 23(2):153-64, vi. PubMed ID: 15694744
[TBL] [Abstract][Full Text] [Related]
3. [Turbid serum].
Füessl HS
MMW Fortschr Med; 2004 Apr; 146(14):49-50. PubMed ID: 15344762
[No Abstract] [Full Text] [Related]
4. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.
Smelt AH; de Beer F
Semin Vasc Med; 2004 Aug; 4(3):249-57. PubMed ID: 15630634
[TBL] [Abstract][Full Text] [Related]
5. Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
Cho EJ; Min YJ; Oh MS; Kwon JE; Kim JE; Kim CJ
Am J Cardiol; 2011 Mar; 107(5):793-6. PubMed ID: 21247547
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Landry P; Dimitri E; Tessier S; Légaré N
J Clin Psychopharmacol; 2008 Jun; 28(3):348-9. PubMed ID: 18480696
[No Abstract] [Full Text] [Related]
7. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
9. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
[TBL] [Abstract][Full Text] [Related]
10. [From gene to disease; apolipoprotein E2 and familial dysbetalipoproteinemia].
Smelt AH
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):157-9. PubMed ID: 12635547
[TBL] [Abstract][Full Text] [Related]
11. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.
Koopal C; Marais AD; Visseren FL
Curr Opin Endocrinol Diabetes Obes; 2017 Apr; 24(2):133-139. PubMed ID: 28098593
[TBL] [Abstract][Full Text] [Related]
12. Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. fruit in hyperlipidemic rats.
Ghule BV; Ghante MH; Saoji AN; Yeole PG
J Ethnopharmacol; 2009 Jul; 124(2):333-7. PubMed ID: 19397976
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Henry K; Melroe H; Huebesch J; Hermundson J; Simpson J
Lancet; 1998 Sep; 352(9133):1031-2. PubMed ID: 9759748
[No Abstract] [Full Text] [Related]
16. The clinical and laboratory investigation of dysbetalipoproteinemia.
Boot CS; Luvai A; Neely RDG
Crit Rev Clin Lab Sci; 2020 Nov; 57(7):458-469. PubMed ID: 32255405
[TBL] [Abstract][Full Text] [Related]
17. Coronary revascularization and aggressive lipid lowering.
Pershad A; Kratzer S; Cooper A
J Invasive Cardiol; 1999 Feb; 11(2):87-9. PubMed ID: 10745488
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
19. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Satoh M; Minami Y; Takahashi Y; Tabuchi T; Itoh T; Nakamura M
Clin Sci (Lond); 2009 May; 116(11):827-35. PubMed ID: 19090788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
